Omeros (OMER) said Wednesday the results of a study evaluating the efficacy and safety of its investigational drug narsoplimab to treat hematopoietic stem...
Omeros (OMER) reported a Q4 adjusted net loss of $0.37 per share late Tuesday, compared with a loss of $0.36 per share in Q3. The biopharmaceutical...
Omeros (OMER) said late Wednesday it has submitted a briefing package to the US Food and Drug Administration after the agency raised concerns about...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | The Omeros Building Seattle, Washington 98119 |
| Phone | +1 206 676-5000 |
| Number of Employees | 236 |
| Recent SEC Filing | 05/10/2022 10-Q |
| Chairman, President & Chief Executive Officer | Gregory A. Demopulos |
| Chief Financial Officer, Treasurer & VP | Michael A. Jacobsen |
| Chief Scientific Officer & Vice President-Science | George A. Gaitanaris |
| Chief Medical Officer & Vice President | J. Steven Whitaker |
| Price Open | $2.92 |
| Previous Close | $2.88 |
| 52 Week Range | $2.50 - 16.62 |
| Market Capitalization | $176.3 M |
| Shares Outstanding | 62.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 1.04 |
| Earnings per Share | -$1.79 |
| Beta vs. S&P 500 | N/A |
| Revenue | $29.9 M |
| Net Profit Margin | -167.35% |
| Return on Equity | 75.62% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
